Public pharma v abusive prices: the case of the latest HIV-prevention drug
ALAN ROSSI SILVA argues that Gilead’s HIV prevention drug, while promising, highlights systemic failures in the pharmaceutical industry, showing the need to shift towards state-owned drug development and production
The welcome news that Cuba has finally been removed from the State Sponsors of Terrorism list is tempered by the fact that Donald Trump, the man who put it there, is returning to the White House, warns NATASHA HICKMAN
Thanks to impressive progress in Britain with wind and solar generation, clean electricity now costs a fraction of the price of gas — yet the current system keeps bills artificially high to protect fossil fuels, writes TOM HARDY
By spreading race-based conspiracy theories, the billionaire tycoon turned right-wing provocateur has been seriously undermining the case against those who really did let victims of the grooming gangs down, writes SOLOMON HUGHES
Many Western countries are grappling with deep political instability. What are the causes of this, and what could be a possible way forward? asks MARC VANDEPITTE
KEITH BENNETT explains why, despite its present meagre economic outcomes, an honest and fruitful partnership with China is worth pursuing
Nick Wright talks to photographer and author JANINA STRUK
LENACAPAVIR, an injectable antiretroviral drug developed by Gilead Sciences, recently made headlines after a Phase 3 clinical trial in South Africa and Uganda showed it to be 100 per cent effective in preventing HIV among women and adolescent girls.
Though hailed as a breakthrough in HIV prevention, lenacapavir serves as a stark reminder of the problems with the pricing of life-saving medicines.
While further data from this study and results from studies involving other populations are needed, lenacapavir could be considered the most durable HIV prevention method to show efficacy among women — a population for who biomedical HIV prevention evidence has been severely limited.
Similar stories
Despite miraculous trial results showing new treatment could halt transmission, corporate greed and patent laws condemn millions to preventable infection and death, write ROX MIDDLETON, LIAM SHAW and MIRIAM GAUNTLETT
